Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6166197 | BIOGEN IDEC | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
Dec, 2017
(6 years ago) | |
US7101993 | BIOGEN IDEC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(7 months ago) | |
US7838657 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Jul, 2027
(3 years from now) | |
US8361977 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing |
May, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6210892 | BIOGEN IDEC | Alteration of cellular behavior by antisense modulation of mRNA processing |
Oct, 2018
(5 years ago) | |
US10266822 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(1 year, 7 months from now) | |
US8110560 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(1 year, 7 months from now) | |
US9717750 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jun, 2030
(6 years from now) | |
US8980853 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Nov, 2030
(6 years from now) | |
US9926559 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jan, 2034
(9 years from now) | |
US10436802 | BIOGEN IDEC | Methods for treating spinal muscular atrophy |
Sep, 2035
(11 years from now) |
Spinraza is owned by Biogen Idec.
Spinraza contains Nusinersen Sodium.
Spinraza has a total of 11 drug patents out of which 3 drug patents have expired.
Expired drug patents of Spinraza are:
Spinraza was authorised for market use on 23 December, 2016.
Spinraza is available in solution;intrathecal dosage forms.
Spinraza can be used as treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna, treatment of infantile-onset spinal muscular atrophy, treatment of spinal muscular atrophy.
Drug patent challenges can be filed against Spinraza from 23 December, 2020.
The generics of Spinraza are possible to be released after 11 September, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-226) | May 14, 2021 |
Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Treatment: Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; Treatment of spinal muscular atrophy; Treatment of infantile-onset spinal muscular atrophy
Dosage: SOLUTION;INTRATHECAL